On December 12, 2022, Novozymes and Chr. Hansen announced that they have entered into an agreement to create a leading global biosolutions partner through a statutory merger of the two companies.
The completion of the proposed merger is subject to, inter alia, approval by the extraordinary general meetings of Novozymes and Chr. Hansen respectively, as well as customary merger control and other regulatory approvals from relevant authorities.
Please see below for documents and other relevant information regarding the proposed merger.